P193 Clinical features of patients with active ankylosing spondylitis who did not respond to adalimumab but responded to ixekizumab: a post-hoc analysis
Sign Up to like & getrecommendations! Published in 2021 at "Rheumatology"
DOI: 10.1093/rheumatology/keab247.188
Abstract: Background/Aims Biologic treatment in ankylosing spondylitis (AS) are currently limited to TNF and IL-17A inhibitors (IL-17Ai). It is unknown whether there are predictors of AS patients who only respond to 1 of these mechanisms of… read more here.
Keywords: ixe; eli lilly; novartis; shareholder ... See more keywords
P127 Baricitinib Efficacy in Moderate Rheumatoid Arthritis - A Post-hoc Analysis from two Phase III Trials
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.168
Abstract: Baricitinib, an oral selective JAK 1/2 inhibitor, is approved for treating adults with moderate-to-severe active rheumatoid arthritis (RA). This analysis aims to report the efficacy of baricitinib in patients with moderate RA at weeks (W)12… read more here.
Keywords: lilly company; analysis; eli lilly; research support ... See more keywords
P131 Time to Discontinuation and Effectiveness with Baricitinib in Rheumatoid Arthritis: 12-Month European Data from a Multinational, Prospective, Observational Study
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.172
Abstract: RA-BE-REAL is a 3-year, multinational, prospective, observational study of adult patients with rheumatoid arthritis (RA) evaluating time-to-discontinuation of initial RA treatment. Baricitinib (BARI), an oral selective JAK1/2 inhibitor, is approved for the treatment of adults… read more here.
Keywords: time; lilly company; eli lilly; discontinuation ... See more keywords
P169 Treatment effects of ixekizumab and adalimumab at the individual digit level with nail and distal interphalangeal joint involvement in patients with psoriatic arthritis
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.210
Abstract: Psoriatic nail disease is intimately linked to adjacent distal interphalangeal joint (DIP) disease, and it is important to ascertain whether DIP-nail complex behaves differently under different biological therapies. The aim of this analysis is to… read more here.
Keywords: lilly company; novartis; involvement; janssen ... See more keywords
P184 A 24-month prospective psoriatic arthritis observational study of persistence of treatment - interim analysis of baseline characteristics
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.225
Abstract: Ixekizumab (ixe), a highly selective interleukin (IL)-17A monoclonal antibody, has been approved for treatment of psoriatic arthritis (PsA). However, there is limited real-world evidence (RWE) available for ixe. PRO-SPIRIT is the first large-sample prospective observational… read more here.
Keywords: lilly company; treatment; eli lilly; research support ... See more keywords
P164 Do real-world treatment patterns reflect PsA recommendations? Results from the PRO-SPIRIT study
Sign Up to like & getrecommendations! Published in 2025 at "Rheumatology"
DOI: 10.1093/rheumatology/keaf142.201
Abstract: The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the European Alliance of Associations for Rheumatology (EULAR) developed recommendation sets for psoriatic arthritis (PsA) treatment based on current evidence. All biologic… read more here.
Keywords: eli lilly; treatment; pro spirit; lilly company ... See more keywords
P166 Effectiveness of b/tsDMARDs including ixekizumab per line of therapy and concomitant csDMARD in psoriatic arthritis: real-world data from a prospective observational study
Sign Up to like & getrecommendations! Published in 2025 at "Rheumatology"
DOI: 10.1093/rheumatology/keaf142.203
Abstract: Treatment (tx) guidelines for PsA recommend biologic DMARDs (bDMARDs) or targeted synthetic (ts) DMARDs after inadequate response to conventional synthetic DMARDs (csDMARDs). In clinical studies, ixekizumab (IXE) has shown efficacy in patients (pts) with PsA… read more here.
Keywords: eli lilly; real world; ucb pharma; lilly company ... See more keywords
E097 Early (3-month) and maintained (12-month) comparative effectiveness of five different classes of advanced therapies in a large multinational cohort of real-world psoriatic arthritis patients
Sign Up to like & getrecommendations! Published in 2025 at "Rheumatology"
DOI: 10.1093/rheumatology/keaf142.332
Abstract: The primary objective was to report persistence at 24 months among patients who initiated a new b/tsDMARD. Secondary endpoints included descriptive and comparative effectiveness and survival data at 3, 12, and 24 months. The analysis… read more here.
Keywords: eli lilly; tnfi; lilly company; comparative effectiveness ... See more keywords
FRI0096 Durability and maintenance of efficacy following prolonged treatment with baricitinib
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1311
Abstract: Background Baricitinib (bari) demonstrated clinical efficacy in Ph3 trials in RA patients (pts) naïve to DMARDs (RA-BEGIN1); and in RA pts with inadequate response to conventional synthetic DMARDs (RA-BEAM2 and RA-BUILD3) or biologic DMARDs (RA-BEACON4).… read more here.
Keywords: response; lilly company; eli lilly; durability ... See more keywords
FRI0090 Analysis of neutrophils, lymphocytes, and platelets in pooled phase 2 and phase 3 studies of baricitinib for rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1325
Abstract: Background Rheumatoid arthritis (RA) is associated with increased neutrophil levels1 and platelet2 counts and decreased lymphocyte levels.1,3 Baricitinib (bari) is a selective and reversible Janus kinase (JAK)1/JAK2 inhibitor in development for patients (pts) with moderate… read more here.
Keywords: eli lilly; lilly company; phase; employee eli ... See more keywords
AB0281 Characterization of changes in lymphocyte subsets in baricitinib-treated patients with early, dmard naÏve, rheumatoid arthritis in a phase 3 study
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1336
Abstract: Background In RA-BEGIN (NCT01711359), baricitinib (bari), an oral Janus Kinase (JAK)1/JAK2 inhibitor, improved signs and symptoms of moderately to severely active RA in patients (pts) who had received no or limited prior csDMARD and no… read more here.
Keywords: lilly company; eli lilly; mtx; cell ... See more keywords